Simbrinza | Beye

Compare IOP Reduction

15 products »

Home > Ophthalmic Drugs > IOP Reduction

Simbrinza

Simbrinza

Alcon, a Novartis Division

Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

TOP

Description

Related Products

Details

Company

At-a-Glance

Mechanism of Action: Brinzolamide inhibits carbonic anhydrase in the ciliary processes of the eye to decrease aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide has a peak ocular hypotensive effect occurring at 2 to 3 hours post-dosing. Fluorophotometric studies in animals and humans suggest that brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. Brimonidine tartrate has a peak ocular hypotensive effect occurring at two hours post-dosing. The result is a reduction in intraocular pressure (IOP).
Dosage: One drop in the affected eye(s) three times daily

Details

FDA

Yes

CE Mark

Not specified

Active Ingredients

Brinzolamide/brimonidine tartrate

Application

Topical

Status

Prescription

Strength

1%/0.2%

Company Information

Contact the company for additional information, availability, or pricing:

Alcon, a Novartis Division

alcon.com

6201 South Freeway

Fort Worth, TX 76134

Compare IOP Reduction »

15 products »

View All IOP Reduction »

15 products »

Privacy | Terms & Conditions Ⓒ 2024 Beye, LLC. All rights reserved.

This content is intended for health care professionals and providers only. The information contained on Beye.com, including text, graphics, images, and interactive activities, is for informational purposes only, and is not intended to be a substitute for professional medical advice. Beye LLC, via its Editors and Publisher, accepts no responsibility for any injury or damage to persons or property occasioned through the implementation of any ideas or use of any product described herein. Although great care is taken to ensure that all information is accurate, it is recommended that readers seek independent verification of advice on drugs and other product usage, surgical techniques and clinical processes prior to their use. References made in article may indicate usage of medical equipment or drugs at dosages, for periods of time, and in combination not included in the current prescribing information. Inclusion of advertising materials on the website thereof, does not constitute and representation or guarantee by Beye LLC of the quality of such products, or of the claims made.